2018-11-15T12:20:04-06:00 2017-12-31 560747981 DIXON HUGHES GOODMAN LLP 901 EAST CARY STREET SUITE 1000 RICHMOND VA 23219 990 2017-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 MARIA C FREIRE PHD PRESIDENT 3014025311 2018-11-14 1 LORI K COCHRAN P00853221 8042827636 2018-11-14 4.16.67.16 2018-11-14 16:34:11 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 3CD412B09983E39150554DEC6362464A9D6A3E5C 2017 2018-06-14 16:35:46Z MARIA C FREIRE PHD 11400 ROCKVILLE PIKE NO 600 NORTH BETHESDA MD 20852 252508965 0 X HTTP://WWW.FNIH.ORG X 1996 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES. 26 25 56 0 0 0 82860385 61322159 122392 111660 479385 1398198 64980 46023 83527142 62878040 23228128 34963149 0 0 6221610 7128157 0 0 208003 17947728 14572507 47397466 56663813 36129676 6214227 116383923 120432415 13155593 9944796 103228330 110487619 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. THE BOARD HAS AN EXECUTIVE COMMITTEE WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. 0 0 49803065 34087568 111660 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS -ANDREW LEE AT AGE 22, ANDREW LEE IS DRIVEN. FOLLOWING HIS HLRCC DIAGNOSIS, ANDREW ESTABLISHED THE NOT-FOR-PROFIT DRIVEN TO CURE, INC. HE NOW TRAVELS THE COUNTRY ATTENDING CAR EVENTS TO RAISE VISIBILITY AND FUNDING FOR RARE KIDNEY CANCERS. IN DECEMBER 2017, ANDREW PRESENTED A $100,000 CHECK TO MARIA C. FREIRE, PH.D., FNIH PRESIDENT AND EXECUTIVE DIRECTOR. THIS DONATION, IN ADDITION TO A $200,000 GIFT MADE IN 2016, WILL FURTHER CUTTING-EDGE RESEARCH ON RARE KIDNEY CANCER CONDUCTED BY THE NATIONAL CANCER INSTITUTE (NCI) AT THE NIH CLINICAL CENTER. "THANKS TO FNIH'S MISSION, THE NEEDED FUNDING CAN BE TARGETED TO THE RESEARCH OF RARE CANCERS LIKE HLRCC. WE LOOK FORWARD TO WORKING WITH THE FNIH IN THE YEARS AHEAD TO HELP FUND OTHER RARE CANCERS AND DISEASES IN ORDER TO HELP MORE PATIENTS," SAID ANDREW. LEARN MORE AT FNIH.ORG/DRIVENTOCURE.MS. CAROL-ANN HARRISMS. CAROL-ANN HARRIS OF FORT LEE, NJ, ADVANCES MUSCULAR DYSTROPHY RESEARCH THROUGH THE CARMOLLNAT ENDOWMENT AT THE FNIH. MS. CAROL-ANN HARRIS SAID, "MUSCULAR DYSTROPHY HAS AFFECTED MY FAMILY FOR AT LEAST SEVEN GENERATIONS. I FELT IT WAS MY CALLING TO HONOR MY LOVED ONES BY INVESTING IN THE FNIH SO THAT IMPORTANT RESEARCH CAN PROPEL THIS FIELD FORWARD AND HELP FUTURE PATIENTS AND THEIR FAMILIES IN THE YEARS TO COME."BARBARA LAZIO, M.D., AND MR. MATTHEW SCHER BARBARA LAZIO, M.D., AND MR. MATTHEW SCHER OF OLYMPIA, WA FURTHER CANCER RESEARCH BY DONATING ANNUALLY TO THE FNIH IN HONOR OF THEIR MOTHERS, WHO PASSED AWAY FROM THE DISEASE. DR. LAZIO SAID, "AFTER LOSING SOME OF OUR CLOSEST FAMILY MEMBERS AND FRIENDS TO CANCER, WE FELT WE NEEDED TO SUPPORT ONGOING RESEARCH TO BENEFIT FUTURE CANCER PATIENTS. THERE ARE MANY CHARITIES SOLICITING FUNDS FOR CANCER RESEARCH, BUT WE FELT BY INVESTING IN THE FNIH, OUR MONEY WOULD BE APPLIED TO THE MOST HIGHLY VETTED AND INNOVATIVE RESEARCH. WE REALLY JUST WANT TO KEEP THE FIRE BURNING, SUPPORT THE INNOVATORS, SEE THESE BABY STEPS DEVELOP INTO SOMETHING THAT CAN EVENTUALLY IMPACT A PERSON'S LIFE."NATIONAL INSTITUTES OF HEALTH (NIH) CONGRESS CHARTERED THE FNIH TO RAISE PRIVATE FUNDS TO SUPPORT THE WORLD'S LARGEST BIOMEDICAL RESEARCH AGENCY, THE NIH. THE FNIH LEVERAGES THE KNOWHOW AND RESOURCES OF THE PRIVATE SECTOR TO WORK WITH THE NIH TO TACKLE COMPLEX BIOMEDICAL CHALLENGES. IN 2017, THE FNIH, NIH, U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND 12 BIOPHARMACEUTICAL COMPANIES LAUNCHED THE HISTORIC $220 MILLION PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT) TO BETTER UNDERSTAND HOW TO HARNESS THE IMMUNE SYSTEM TO ATTACK CANCER. LEARN MORE AT FNIH.ORG/PACT. "THE FNIH MAKES IT POSSIBLE FOR THE NIH, AS A GOVERNMENT FACILITY, TO WORK WITH THE PRIVATE SECTOR TO ANSWER SOME OF THE WORLD'S MOST PRESSING HEALTH QUESTIONS. THROUGH INNOVATIVE RESEARCH PARTNERSHIPS, THE NIH AND FNIH ARE ABLE TO FUEL THE BIOMEDICAL DISCOVERIES NEEDED FOR BETTER DIAGNOSIS, PREVENTION, TREATMENT AND CURE OF DISEASE. WORKING WITH THE FNIH IS VITAL TO THE RESEARCH ENTERPRISE," SAID FRANCIS COLLINS, M.D., PH.D., NIH DIRECTOR. NATIONAL INSTITUTE ON AGING (NIA) THE NIA, UNDER THE INSPIRED LEADERSHIP OF DIRECTOR RICHARD HODES, M.D., HAS BEEN ONE OF THE FNIH'S MOST SIGNIFICANT AND LONGSTANDING PARTNERS. OVER THE PAST DECADE, THE NIA AND THE FNIH HAVE DEVELOPED NEW COLLABORATION MODELS, GOVERNANCE STRUCTURES AND DATA-SHARING POLICIES FOR SUCH GROUNDBREAKING PROGRAMS AS THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) AND THE ACCELERATING MEDICINES PARTNERSHIP (AMP). DR. HODES REFLECTED ON THIS PARTNERSHIP WITH THE FNIH: "THE BENEFIT OF COLLABORATIONS, SCIENTIFIC MEETINGS AND OTHER SUPPORT PROVIDED TO NIH THROUGH THE FOUNDATION IS NOT LIMITED TO THE INSTITUTE OR INSTITUTES WHOSE WORK IS BEING FACILITATED. THESE EFFORTS GALVANIZE ALL PARTNERS IN MOVING TOWARD SHARED GOALS. WE HAVE SEEN THIS IN SEVERAL AREAS, MOST RECENTLY IN THE EMERGENCE OF THE NEW DISCIPLINE OF GEROSCIENCE, WHERE FOUNDATION EFFORTS HAVE FACILITATED CONFERENCES THAT HAVE HELPED DEVELOP NEW SYNERGY BETWEEN RESEARCHERS IN THE BASIC BIOLOGY OF AGING AND SCIENTISTS FOCUSED ON SPECIFIC DISEASES ASSOCIATED WITH ADVANCED AGE, SUCH AS CANCER AND HEART DISEASE. THIS NEW APPROACH HAS ENHANCED THE RECOGNITION OF AGING AS THE CRITICAL RISK FACTOR UNDERLYING DISEASE DEVELOPMENT IN MANY CASES AND HAS FOSTERED NEW CONNECTIONS AMONG PUBLIC AND PRIVATE SECTOR SCIENTISTS SEEKING TO REDUCE DISEASE RISK AND IMPROVE HEALTH FOR OLDER PEOPLE."U.S. FOOD AND DRUG ADMINISTRATION (FDA)THE FDA, THE U.S. REGULATORY AGENCY FOR BIOMEDICAL TECHNOLOGIES, IS A PRIMARY PARTNER ACTIVELY ENGAGED IN FNIH PUBLIC-PRIVATE CONSORTIA THAT FORMULATE AND LEAD CUTTING-EDGE RESEARCH PROGRAMS. THE FNIH BIOMARKERS CONSORTIUM MANAGES MANY OF THESE PROGRAMS, WHICH OFTEN HAVE REGULATORY IMPLICATIONS. THE MISSION OF THE BIOMARKERS CONSORTIUM IS TO DISCOVER, DEVELOP AND SEEK REGULATORY APPROVAL OF BIOLOGICAL MARKERS (BIOMARKERS) TO SUPPORT DEVELOPMENT OF NEW DIAGNOSTIC TOOLS AND DRUGS WITHIN FOUR KEY AREAS: CANCER, INFLAMMATION AND IMMUNITY, METABOLIC DISORDERS AND NEUROSCIENCE. IN 2017, THE BIOMARKERS CONSORTIUM REACHED SEVERAL MILESTONES, INCLUDING THE PUBLICATION OF A FRAMEWORK TO GUIDE BIOMARKER QUALIFICATION IN SCIENCE TRANSLATIONAL MEDICINE, AS WELL AS SUBMITTING RECOMMENDATIONS TO THE FDA TO GUIDE DRUG DEVELOPMENT FOR SERIOUS HOSPITAL ACQUIRED BACTERIAL INFECTIONS. LEARN MORE ABOUT BIOMARKERS CONSORTIUM PROJECTS AT FNIH.ORG/BIOMARKERSCONSORTIUM.BILL & MELINDA GATES FOUNDATIONADDRESSING SOME OF THE WORLD'S MOST PRESSING HEALTH CHALLENGES, INCLUDING TUBERCULOSIS AND MALARIA, REQUIRES THE PROFICIENCY OF INDOMITABLE SCIENTISTS BACKED BY EXCELLENT PROJECT MANAGEMENT AND STABLE FINANCIAL SUPPORT. FOR MORE THAN A DECADE, THE BILL & MELINDA GATES FOUNDATION (GATES FOUNDATION) HAS WORKED WITH THE FNIH TO DEVELOP STRONG ECOSYSTEMS THAT UNDERPIN SCIENTIFIC DISCOVERY AND FOSTER CREATION OF EMERGING TECHNOLOGIES TO PROVIDE NOVEL SOLUTIONS TO FIGHT DISEASE.IN 2017, AMONG OTHER KEY ACCOMPLISHMENTS, THIS WORK RESULTED IN THE PUBLICATION OF THE GUIDING PRINCIPLES FOR SPONSORS AND SUPPORTERS OF GENE DRIVE RESEARCH IN SCIENCE. CONSIDERED AN EMERGING TECHNOLOGY, GENE DRIVE CAN BE USED TO PROMOTE THE PREFERENTIAL INHERITANCE OF A BENEFICIAL TRAIT, THEREBY INCREASING ITS PREVALENCE IN A POPULATION. THE DEVELOPERS AND SIGNATORIES OF THESE GUIDING PRINCIPLES ARE COMMITTING TO SUPPORT RESEARCH OF THE HIGHEST SCIENTIFIC AND ETHICAL QUALITY, INSPIRE A TRANSPARENT APPROACH AND BACK RELEVANT BIOSAFETY MEASURES AND BEST PRACTICES. LEARN MORE ABOUT THIS WORK AT FNIH.ORG/GENEDRIVEPRINCIPLES.THE GATES FOUNDATION'S STEVEN BUCHSBAUM, PH.D., REFLECTED ON THE FOUNDATION'S LONGSTANDING PARTNERSHIP WITH THE FNIH: "THE FNIH WAS, IN THE VERY EARLY DAYS OF THE GATES FOUNDATION, A KEY PARTNER THAT WE CHOSE TO FIRST BEGIN INVESTING IN BASIC SCIENCE FOR GLOBAL HEALTH. THAT STARTED WITH THE ORIGINAL GRAND CHALLENGES IN GLOBAL HEALTH, WHICH THE FNIH WAS OUR KEY PARTNER IN FORMULATING AND EXECUTING. HAVING HAD THE OPPORTUNITY TO SEE PROJECTS EVOLVE AND MATURE OVER MORE THAN A DECADE, THERE ARE A NUMBER OF THEM THAT WERE CALLED FOR, SELECTED, INVESTED AND NURTURED EITHER BY THE FNIH THEMSELVES OR JOINTLY WITH US THAT ARE INCREDIBLY PROMISING IN THE SENSE THAT THEY ARE TRANSFORMATIONAL NEW TOOLS FOR GLOBAL HEALTH. ONE EXAMPLE IS THE ELIMINATE DENGUE PROJECT (NOW CALLED THE WORLD MOSQUITO PROGRAM) AND ANOTHER IS THE TARGET MALARIA INITIATIVE. BUT PERHAPS MORE THAN THAT, AND HARDER TO MEASURE AND DIRECTLY ATTRIBUTE, IS REALLY JUST THE CHANGE IN THE SCIENTIFIC COMMUNITY IN THE SENSE OF THE EXCITEMENT, ATTENTION PAID AND AMOUNT OF RESEARCH THAT IS DONE ON HEALTH CONDITIONS THAT AFFECT THE MAJORITY OF THE POPULATION IN THE WORLD, BUT PARTICULARLY THOSE THAT ARE POOR AND UNDERSERVED." 958145 678997 SEE SCHEDULE O, PROGRAM TWO, EDUCATION, TRAINING AND PATIENT SUPPORT PROGRAMSPROGRAM TWO - EDUCATION, TRAINING AND PATIENT SUPPORT PROGRAMS - BUFFY CAFRITZTHE CULTURAL AND PHILANTHROPIC CONTRIBUTIONS OF BUFFY CAFRITZ ARE EVER PRESENT AROUND THE COUNTRY, ESPECIALLY JUST 10 MILES NORTH OF WASHINGTON, D.C. ON THE NIH CAMPUS IN BETHESDA, MD. MRS. CAFRITZ'S UNWAVERING COMMITMENT TO THE FNIH HAS SUPPORTED STUDENTS, PATIENTS AND RESEARCHERS AT THE NIH FOR NEARLY TWO DECADES. SHE AND HER HUSBAND HAVE HELPED STUDENTS INTERESTED IN PARKINSON'S DISEASE TRAIN WITH RENOWNED SCIENTISTS BY FUNDING THE NIH MEDICAL RESEARCH SCHOLARS PROGRAM, THUS SUPPORTING A NEW GENERATION OF CLINICIAN-SCIENTISTS. MRS. CAFRITZ ALSO SPONSORS A ROOM AT THE EDMOND J. SAFRA FAMILY LODGE JUST FOOTSTEPS AWAY FROM THE NIH CLINICAL CENTER, SO THAT PATIENTS AND THEIR FAMILIES CAN STAY TOGETHER DURING TREATMENT. MRS. CAFRITZ AND THE BUFFY AND WILLIAM CAFRITZ FAMILY FOUNDATION'S COMMITMENT TO BIOMEDICINE EXTENDS TO RESEARCH IN THE LABORATORY. IN 2017, THEIR SUPPORT CREATED A FIVE-YEAR COMPETITIVE GRANT PROGRAM AT THE NCI TO DEVELOP HIGHLY INNOVATIVE APPROACHES AND TECHNOLOGIES FOR KIDNEY CANCER. THROUGH HER DEDICATION TO THIS SIGNIFICANT WORK, MRS. CAFRITZ'S PRESENCE IN BIOMEDICAL RESEARCH WILL BE FELT FOR GENERATIONS TO COME.AMGEN FOUNDATION AND DORIS DUKE CHARITABLE FOUNDATIONTHE FNIH SUPPORTS TRAINING PROGRAMS AT THE NIH THAT ENABLE STUDENTS INTERESTED IN BIOMEDICINE TO WORK CLOSELY WITH SOME OF THE WORLD'S LEADING RESEARCHERS. THESE PROGRAMS ARE MADE POSSIBLE WITH PARTNERS INCLUDING THE AMGEN FOUNDATION AND THE DORIS DUKE CHARITABLE FOUNDATION."BY PARTNERING WITH THE FNIH IN ADDITION TO INSTITUTIONS SUCH AS HARVARD, MIT AND CAMBRIDGE WE ARE OPENING THE DOOR TO GROUND-BREAKING RESEARCH OPPORTUNITIES IN BIOMEDICAL RESEARCH THAT CONTINUE TO ADVANCE HUMAN HEALTH IN UNTOLD WAYS. IF YOUR MISSION IS TO INSPIRE AND TRAIN THE NEXT GENERATION IN BIOMEDICAL RESEARCH OR TO ADVANCE SCIENTIFIC BREAKTHROUGHS INTO HUMAN HEALTH THE FNIH NEEDS TO BE ON YOUR SHORT LIST AS AN ORGANIZATION WORTH PARTNERING WITH," SAID SCOTT HEIMLICH, ED.D. VICE PRESIDENT, AMGEN FOUNDATION. "OUR PARTNERSHIP WITH THE FNIH SUPPORTS THE MEDICAL RESEARCH SCHOLARS PROGRAM, WHICH GIVES MEDICAL STUDENTS A HANDS-ON CLINICAL RESEARCH EXPERIENCE UNDER THE GUIDANCE OF SUCCESSFUL SCIENTISTS. WE ARE PROUD TO SUPPORT THIS PROGRAM AS AN AVENUE FOR IGNITING IN STUDENTS A PASSION FOR RESEARCH THAT CAN TRANSLATE INTO A PRODUCTIVE, LIFELONG CAREER AS A PHYSICIAN SCIENTIST," SAID BETSY MYERS, PH.D., PROGRAM DIRECTOR FOR MEDICAL RESEARCH, DORIS DUKE CHARITABLE FOUNDATION. 813509 196584 SEE SCHEDULE O, PROGRAM THREE, MEMORIALS, AWARDS AND EVENTSPROGRAM THREE - MEMORIALS, AWARDS AND EVENTS -THE FNIH MANAGES AND ORGANIZES SCIENTIFIC MEETINGS, AWARDS AND EVENTS THROUGHOUT THE YEAR. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, THE FNIH FACILITATED MORE THAN 60 EVENTS IN 2017 THAT SPANNED DOZENS OF FIELDS OF RESEARCH. THIS INCLUDED THE 5TH ANNUAL PRESENTATION OF THE LURIE PRIZE IN BIOMEDICAL SCIENCES, A $100,000 AWARD RECOGNIZING OUTSTANDING ACHIEVEMENT BY A PROMISING YOUNG SCIENTIST IN BIOMEDICAL RESEARCH. IN MAY 2017 THOUGHT LEADERS FROM THE NIH, PIONEERS IN BIOMEDICAL SCIENCE, THE BIOTECH AND PHARMACEUTICAL INDUSTRIES, PHILANTHROPISTS AND BUSINESS EXECUTIVES CONVENED AT THE ORGANIZATION OF AMERICAN STATES IN WASHINGTON, D.C. FOR THE PRESENTATION OF THE LURIE PRIZE AT THE FNIH AWARD CEREMONY. WOLF BLITZER, AWARD-WINNING JOURNALIST AND TELEVISION NEWS ANCHOR, WAS THE EVENING'S MASTER OF CEREMONIES. THE 2017 LURIE PRIZE WAS AWARDED TO DAVID M. SABATINI, M.D., PH.D., MEMBER OF THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH AND PROFESSOR OF BIOLOGY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY. DR. SABATINI DISCOVERED THE MTOR (MECHANISTIC TARGET OF RAPAMYCIN) CELLULAR PATHWAY AS A KEY REGULATOR OF GROWTH AND METABOLISM IN RESPONSE TO NUTRIENTS. AT THE FNIH FALL BOARD DINNER IN OCTOBER 2017, THE FNIH PRESENTED THE 2ND CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RICHARD J. HODES, M.D., DIRECTOR OF THE NIA AND ELI LILLY AND COMPANY (LILLY). THE AWARD RECOGNIZES PERSONS AND/OR ORGANIZATIONS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FNIH'S WORK TO BUILD, IMPLEMENT AND NURTURE PRIVATE-PUBLIC PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH. THROUGH THEIR LONGSTANDING WORK WITH THE FNIH OVER MORE THAN A DECADE, DR. HODES AND LILLY HAVE ADVANCED TRAILBLAZING BIOMEDICAL RESEARCH IN CRITICAL DISEASE AREAS, INCLUDING AGE-RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, AND HELPED STRUCTURE INNOVATIVE PUBLIC-PRIVATE PARTNERSHIPS. THE MCKNIGHT BRAIN RESEARCH FOUNDATION (MBRF)'S DECADE-LONG PARTNERSHIP WITH THE FNIH HAS EXPANDED UNDERSTANDING OF HOW PEOPLE THINK AS THEY AGE, THROUGH CO-SPONSORSHIP OF THE RESEARCH PARTNERSHIP IN COGNITIVE AGING AND THREE COGNITIVE AGING SUMMITS WITH THE NIA. THE THIRD SUMMIT WAS HELD IN APRIL 2017. "THIS PARTNERSHIP HAS FACILITATED EXPLORATION OF NEW AVENUES OF POTENTIAL RESEARCH WITHIN THE SCIENTIFIC COMMUNITY, WHICH COULD LEAD TO THE DEVELOPMENT OF PHARMACOLOGICAL AND BEHAVIORAL INTERVENTIONS, AND ULTIMATELY IMPROVED OUTCOMES IN COGNITIVE HEALTH. A VERY IMPORTANT OUTCOME HAS ALSO BEEN RAISING THE LEVEL OF AWARENESS WITHIN THE SCIENTIFIC COMMUNITY AND AMONG THE PUBLIC ABOUT THE IMPORTANCE OF THIS RESEARCH AND ITS TREMENDOUS VALUE TO SOCIETY IN PRESERVING AND MAINTAINING COGNITIVE HEALTH."J. LEE DOCKERY, M.D., CHAIR, BOARD OF TRUSTEES, MBRF. 66782 PROGRAM FOUR - CAPITAL PROJECTS - MRS. LILY SAFRA AS LEAD BENEFACTOR OF THE EDMOND J. SAFRA FAMILY LODGE (FAMILY LODGE), MRS. LILY SAFRA HAS MADE HOUSING AVAILABLE FOR ABOUT 130,000 ADULT PATIENTS OF THE NIH CLINICAL CENTER AND THEIR LOVED ONES SINCE 2005. THESE BRAVE PATIENTS TRAVEL WITH THEIR FAMILIES FROM AROUND THE WORLD TO PARTICIPATE IN VITAL RESEARCH AT THE NIH CLINICAL CENTER, WHICH IS KNOWN FOR ITS HISTORY OF MEDICAL BREAKTHROUGHS, INCLUDING THE DEVELOPMENT OF CHEMOTHERAPY FOR CANCER AND THE FIRST AIDS TREATMENT. LOCATED WITHIN WALKING DISTANCE OF THE NIH CLINICAL CENTER, THIS ENGLISH MANOR STYLE RESIDENCE FEATURES 34 SPACIOUS GUEST ROOMS. ITS ELEGANT KITCHEN, LIBRARY, FITNESS AND BUSINESS CENTERS, AND GARDENS, ALONGSIDE ITS DEDICATED ONSITE TEAM, OFFER FAMILIES A HOME-LIKE PLACE OF RESPITE DURING THEIR TIME OF NEED. BY CARING FOR THESE COURAGEOUS FAMILIES, MRS. SAFRA IS ENSURING CRUCIAL BIOMEDICAL RESEARCH RAPIDLY PROGRESSES TO IMPROVE THE HEALTH OF CURRENT PATIENTS AND THOSE IN THE YEARS AHEAD. LEARN MORE ABOUT THE FAMILY LODGE AT FNIH.ORG/FAMILYLODGE. 66782 51641501 1 1 0 1 0 1 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 32 0 1 56 1 0 0 0 0 0 0 0 0 0 0 X 26 25 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI X X DONALD M HILL 3014025311 11400 ROCKVILLE PIKE NORTH BETHESDA MD 20852 DR STEVEN M PAUL CHAIRMAN 1.50 X X 0 0 0 MR STEVEN C MAYER TREASURER 2.00 X X 0 0 0 DR SOLOMON H SNYDER VICE-CHAIRMAN 0.50 X X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X X 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 40.00 X X 430206 0 27000 DR KATHY BLOOMGARDEN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS WILLIAM N CAFRITZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JAMES H DONOVAN BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL L HERRLING BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR THOMAS R INSEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR JUDY LANSING KOVLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR RONALD L KRALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR FREDA C LEWIS-HALL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR EDISON T LIU BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR JOEL S MARCUS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL M MONTRONE BOARD OF DIRECTORS MEMBER 1.00 X 0 0 0 DR MARTIN J MURPHY JR BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DAME JILLIAN SACKLER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR CHARLES A SANDERS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MRS LILY SAFRA BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR ELLEN V SIGAL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MS NINA SOLARZ BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR RUSSELL W STEENBERG BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR PAUL STOFFELS BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR SAMUEL O THIER BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 MR FRED SEIGEL BOARD OF DIRECTORS MEMBER 0.50 X 0 0 0 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 40.00 X 314688 0 27000 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 40.00 X 310988 0 38744 MS JULIE TUNE CFO THROUGH APRIL 2017 40.00 X 184774 0 22430 MS JULIA WOLF-RODDA SENIOR VP OF DEVELOPMENT 40.00 X 211285 0 32672 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 40.00 X 210285 0 32502 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 40.00 X 152986 0 20672 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIPS 40.00 X 208288 0 32573 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 172975 0 29041 DR MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 40.00 X 171195 0 17120 DR ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER, NEUROSCIENCE 40.00 X 161141 0 27608 DR STACEY ADAM DIRECTOR OF CANCER 40.00 X 156878 0 21105 2685689 0 328467 21 0 1 0 SWOG CTI 24 FRANK LLOYD WRIGHT DRIVE PO BOX ANN ARBOR MI 48105 CONDUCTS CLINICAL TRIAL FOR LUNGMAP 10985114 AVID RADIOPHARMACEUTICALS INC 3711 MARKET STREET 7TH FLOOR PHILADELPHIA PA 19104 CONDUCTS CLINICAL TRIAL FOR AMP AD 574750 MARRIOTT BUSINESS SERVICES PO BOX 402642 ATLANTA GA 30384 MEETING SERVICES FOR VARIOUS PROJECTS 562290 CCS ASSOCIATES INC PO BOX 9125 MCLEAN VA 22102 PROFESSIONAL SERVICE FOR VARIOUS RESEARC 237709 OFFICE IMAGES INC 7650 STANDISH PLACE 109 ROCKVILLE MD 20855 PROFESSIONAL SERVICE FOR NEW OFFICE MOVE 226736 16 55500 1110000 60156659 1284335 61322159 ADMINISTRATIVE FEES 561000 111660 111660 111660 1066052 1066052 189739894 189407748 332146 332146 332146 269200 55500 223177 46023 46023 62878040 111660 0 1444221 27501129 27501129 21522 21522 7440498 7440498 2113219 1018284 1084065 10870 3568530 1980845 1504919 82766 361295 185356 163051 12888 704237 372854 321804 9579 380876 170614 210262 75937 62140 13797 54370 54370 121417 34246 87171 13279 2355 10924 22141 8300 13758 83 97154 50680 32702 13772 491771 179199 312572 1969765 1856702 110580 2483 51250 51250 198275 147202 51073 PROGRAM CONTRACTS 10344497 10344497 CONSULTANTS 1249273 1002100 181173 66000 RELOCATION 352047 5000 347047 TEMPORARY SERVICES 183653 159278 24375 -652322 -901300 239416 9562 56663813 51641501 4814309 208003 46693317 25197544 26338796 23480012 90770 154153 2354766 701489 42605 1653277 43080177 69726056 138258 221373 116383923 120432415 8076645 3704459 4474530 3382073 453876 1240626 150542 1617638 13155593 9944796 X 13322940 15970742 86811639 91433211 3093751 3083666 103228330 110487619 116383923 120432415 6214227 1045062 0 X X 0 1 X 1 0 X 59135001 73905546 33961607 82860385 61322159 311184698 59135001 73905546 33961607 82860385 61322159 311184698 142046357 169138341 213728 214303 367897 574125 1066052 2436105 313620803 959090 0.53930 0.49770 X 0 1 0 0 0 0 1 0 0 0 0 PART II-B, LINE 1: FNIH CONSULTED ITS COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION 2 2300 2900 3288329 1 1 0 1 X 9704030 1721204 552828 57336 11920726 9501571 11412 243278 52231 9704030 9616660 10356 -100829 24616 9501571 3381374 6271975 11641 48330 9616660 3491739 14559 -83704 41220 3381374 0.66840 0.25870 0.07290 0 0 1387425 15416 1372009 967341 686073 281268 1653277 CHARITABLE GIFT ANNUITY 144193 DEFERRED LEASE INCENTIVE 1372009 DEFERRED RENT LIABILITY 101436 1617638 X 64419891 1045062 273612 1318674 63101217 -223177 -223177 62878040 57160602 273612 223177 496789 56663813 0 56663813 PART IV, LINE 2B: AS OF 12/31/2017, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $1,240,626 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. PART V, LINE 4: THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2017 AND 2016. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE -223,177. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE 223,177. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 3465311 SOUTH ASIA 0 0 GRANTMAKING 1574091 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 2401096 0 0 0 0 0 0 7440498 0 7440498 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 1682585 WIRE TRANSFER EAST ASIA AND THE PACIFIC RESEARCH 1081979 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 258490 WIRE TRANSFER EAST ASIA AND THE PACIFIC RESEARCH 223478 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH 576459 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH 324262 WIRE TRANSFER EAST ASIA AND THE PACIFIC RESEARCH 140300 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 276761 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 85341 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH 1251179 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH 249196 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 1110269 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 51865 WIRE TRANSFER EAST ASIA AND THE PACIFIC RESEARCH 128334 WIRE TRANSFER 4 10 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. 2017 FNIH AWARD CEREMONY 319700 55500 264200 20998 191766 2018 FNIH AWARD CEREMONY 5000 5000 86 10327 324700 55500 269200 21084 202093 223177 46023 1 BRIGHAM & WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 288550 1 EVALUATION OF THE EFFECTS OF FCRN MUTATIONS ON ANTIBODY HALF-LIFE.+ KIDNEY BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 74950 1 RESEARCH CASE WESTERN RESERVE UNIVERSITY NORD HALL SUITE 615 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(C)(3) 502889 1 CTVIMC2-MOLECULAR IMMUNE CORRELATES CORE CATALYSIS FOUNDATION FOR HEALTH INC 1900 POWELL STREET SUITE 600 EMERYVILLE CA 94608 208602047 501(C)(3) 164678 1 PREDICT TB DONALD DANFORD PLANT SCIENCE CENTER 975 NORTH WARSON ROAD ST LOUIS MO 63132 311584621 501(C)(3) 1187493 1 REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 260743 1 PROFICIENCY TESTING CENTRAL/CTVIMC2 EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 311935084 580566256 501(C)(3) 115000 1 RESEARCH FRED HUTCHINSON CANCER RESEARCH 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 574460 1 CTVIMC2/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SUTH WASHINGTON DC 20036 521983273 501(C)(3) 100000 1 LUNGCANCER PROTOCOL JOHN HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 318058 1 MAL-ED/ CARDIAC TROPONIN MAYO CLINIC (JACKSONVILLE) PO BOX 860334 MINNEAPOLIS MN 554860334 593337028 501(C)(3) 39100 1 RESEARCH NIHCC 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 447424 1 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 742150 1 RESEARCH NIHNEI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 417414 1 RESEARCH NIHNHGRI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 13000 1 RESEARCH NIHNHLBI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 70419 1 RESEARCH NIHNIA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2199696 1 RESEARCH NIHNIAA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 5820190 1 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 4014645 1 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 7283825 1 RESEARCH NIHNIMH 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 1152810 1 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 260915 1 RESEARCH NIHNINR 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 8125 1 RESEARCH NIHOD 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 135094 1 RESEARCH REGENTS OF THE UNIVERISTY OF MICHIGAN 3003 SOUTH STATE STREET 1040 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 170(C)(1) GOVT 260315 1 AMP-T2 DIABETES. DEPOSIT OF METSIM AND FUSION DATA INTO KNOWLEDGE PORTAL RUSH UNIVERSITY MEDICAL CENTER 1700 W VAN BUREN 273 TOB CHICAGO IL 60612 362174823 501(C)(3) 17250 1 RESEARCH SUTTER BAY HOSPITALS DBA CALIFORNIA PACIFIC MEDICAL CENTER 475 BRANNAN STREET SUITE 220 SAN FRANCISCO CA 94107 940562680 501(C)(3) 15870 1 SARCOPENIA UNIVERSITY OF CALIFORNIA SAN FRANCISCO MISSION HALL 550 16TH STREET 2ND FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 262605 1 BONE QUALITY TRUSTEES OF COLUMBIA UNIVERSITY NY PO BOX 29789 NEW YORK NY 100879789 135598093 501(C)(3) 97750 1 RESEARCH UNIVERSITY OF SOUTHERN CALIFORNIA SOTO STREET BUILDING 2001 SOTO STREET LOS ANGELES CA 900899235 911642394 501(C)(3) 654111 1 HD-SCA 30 AWARDS 17 21522 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X 1 0 0 0 0 0 0 0 0 DR MARIA C FREIRE PRESIDENT AND EXECUTIVE DIRECTOR 430206 0 0 0 0 0 27000 0 0 0 457206 0 0 0 DR STEPHANIE JAMES SENIOR VP OF SCIENCE 314688 0 0 0 0 0 27000 0 0 0 341688 0 0 0 MR DAVID WHOLLEY SENIOR VP OF RESEARCH PARTNERSHIPS 308438 0 0 0 2550 0 27000 0 11744 0 349732 0 0 0 MS JULIE TUNE CFO THROUGH APRIL 2017 184399 0 0 0 375 0 18440 0 3990 0 207204 0 0 0 MS JULIA WOLF-RODDA SENIOR VP OF DEVELOPMENT 209285 0 0 0 2000 0 20928 0 11744 0 243957 0 0 0 MR KEVIN A KLOCK VP OF OPERATIONS & GENERAL COUNSEL 202585 0 5000 0 2700 0 20758 0 11744 0 242787 0 0 0 MR ROBERT BALTHASER VICE PRESIDENT OF ADVANCEMENT 152986 0 0 0 0 0 15299 0 5373 0 173658 0 0 0 DR JOSEPH MENETSKI ASSOCIATE VP OF RESEARCH PARTNERSHIP 208288 0 0 0 0 0 20829 0 11744 0 240861 0 0 0 DR KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 169975 0 3000 0 0 0 17297 0 11744 0 202016 0 0 0 DR MICHAEL GOTTLIEB ASSOCIATE DIRECTOR OF SCIENCE 171195 0 0 0 0 0 17120 0 0 0 188315 0 0 0 DR ROSA CANET AVILES SCIENTIFIC PROGRAM MANAGER, NEUROSCI 158641 0 0 0 2500 0 15864 0 11744 0 188749 0 0 0 DR STACEY ADAM DIRECTOR OF CANCER 156878 0 0 0 0 0 15688 0 5417 0 177983 0 0 0 PART I, LINE 4A JULIE TUNE LEFT FNIH IN APRIL OF 2017. SHE RECEIVED A SEVERANCE PAYMENT OF $83,083. X 3 28129 STOCK PRICE X 2 1248661 MARKET PRICE X PAINTINGS 1 6300 X GOODS 1 1045 X WOOD PANEL 1 200 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 DR. FREIRE, PRESIDENT OF THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC. (FNIH), IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE EQUITIES (ARE). MR. JOEL MARCUS, CEO AND CHAIRMAN OF ARE IS A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.